MaxCyte Q4 revenue record $10.2M (+19%), FY2021 $33.9M (+30%); guides 2022 core growth 22-25%

MAXCYTE, INC.

Record Q4 revenue $10.2M (+19% YoY); FY revenue $33.9M (+30% YoY).
Core cell therapy revenue grew 43% in Q4, drug discovery 32%; SPL program revenue $2.5M FY.
Net loss $4.9M Q4, $19.1M FY; EBITDA loss $4.5M Q4, $17.4M FY; stock-based comp $2.4M Q4, $8.0M FY.
2022 guidance: core revenue growth 22-25% YoY, SPL program revenue ~$4M.
SPL partners now 16 covering >95 programs; potential pre-commercial milestones >$1.25B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.